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Angioedema, characterized by intermittent attacks of peripheral edema due to extravasation of fluids into interstitial tissues, results from the release of inflammatory mediators that lead to enhanced permeability of capillaries and venules as well as dilatation of blood vessels.
Clinical characteristics include rapid onset of edema, involvement of tongue, cheeks, upper airways and bowel and asymmetric distribution. 1, 2 C1 esterase inhibitor deficiency has been identified as a possible cause for recurrent angioedema.
3 C1 esterase inhibitor is a serum alpha2 globulin molecule and a member of the serpin family of protease inhibitors produced in hepatocytes. The function of this protein is to inhibit catalytic units of the classic complement pathway. 1 Two forms of this condition have been described, the inherited form usually detected early in life with an autosomal dominant inheritance and the acquired form affecting primarily adults or elderly patients. 4 Acquired C1 esterase inhibitor deficiency has been associated with autoimmune and lymphoproliferative disorders. Treatment of the acute attack often includes use of glucocorticoids, anti-histamines, and, in severe cases, epinephrine. For prophylaxis, androgens in conjunction with treatment of the underlying condition are suggested. This strategy has resulted in a 50% response rate in preventing further attacks in the largest published series of 22 patients with acquired C1 esterase inhibitor deficiency. 1 We discuss the case of a 68-year-old male who first presented with periodic, sudden attacks of angioedema, resulting in swelling of soft tissues in his face, lips and scrotum with intermittent severe abdominal pain at age 60. Family history was negative for similar symptoms. CBC at initial workup was normal. C1 esterase inhibitor levels were low at 0.05 mg/l (normal range at 0.1-0.27) and the patient was diagnosed with C1 esterase inhibitor deficiency. The patient was managed with the androgen stanozolol and the frequency of attacks diminished, but were not eliminated. Approximately 3 years later, on routine follow-up, his platelet count was noted to rise above normal limits and peaked at 1300 Â 10 9 /l. Review of initial bone marrow and in vitro cell culture studies were suggestive of essential thrombocythemia. Cytogenetic examination revealed a normal karyotype. The patient was managed with anagrelide and the platelet count was well controlled. Subsequently, disease progression was noted with splenomegaly, occurrence of blasts in the peripheral blood, as well as development of night sweats and fever. Bone marrow examination showed evidence of significant fibrosis consistent with transformation to myelofibrosis. His past medical history included coronary artery disease with coronary artery bypass grafting as well as hypercholesterolemia requiring treatment with atorvastatine.
The patient went on to receive a nonmyeloablative stem cell transplant from his HLA-identical brother. The preparative regimen consisted of fludarabine 30 mg/m 2 for 5 days and TBI 200 cGy single dose. GVHD prophylaxis consisted of cyclosporine and mycophenolate mofetil. A total of 4.7 Â 10 6 CD34 þ cells/kg body weight were infused. Both donor and recipient were CMV seronegative. The transplant was complicated by internal jugular vein thrombosis, requiring anticoagulation. No VOD or infectious complications occurred during hospitalization. No acute GVHD was noted. The patient developed chronic extensive GVHD of his mouth and skin treated with cyclosporine A, mycophenolate mofetil and prednisone. Bone marrow aspirate and biopsy done 5 months post transplant showed complete morphological remission and resolution of fibrosis. Chimerism analysis of peripheral blood showed the presence of more than 90% donor cells. Another flare of chronic GVHD of liver responded to treatment with azathioprine and prednisone.
With a follow-up of more than 27 months after transplant, there has been no recurrence of angioedema. The C1 esterase inhibitor level 5 months post transplant was normal at 0.4 g/l (0.21-0.39). Further testing at 26 months post transplant showed a sustained normal level of C1 esterase inhibitor of 0.35 g/l.
Our patient had developed angioedema prior to any clinical evidence of a hematological abnormality, suggesting that the processes were independent, although it cannot be excluded that angioedema was the first indication of his myeloproliferative disorder. Acquired C1 esterase inhibitor deficiency reported in the literature has been associated with lympho-and not myeloproliferative disorders. Treatment with androgens resulted in a decrease in the frequency, but not the elimination of attacks in our patient.
It is more likely that our patient's angioedema is related to an acquired, rather than an inherited, deficiency of C1 esterase inhibitor, based on the time of development of his symptoms and the absence of a family history. After the nonmyeloablative stem cell transplant and the achievement of sustained complete engraftment of donor cells, the C1 esterase inhibitor levels in the recipient were normalized, resulting in the complete absence of angioedema attacks more than 2 years later. To our knowledge, this is the first report of correction of this condition with the establishment of donor-derived hematopoiesis. This case also raises the question as to the mechanism of C1 esterase inhibitor production and whether hematopoietic cell derived production of this inhibitor occurs in addition to the previously described hepatocyte derived synthesis of C1 esterase inhibitor.
